Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder

被引：0
|
作者：
Karayal, O.
Citrome, L. [2 ]
Yang, R. [1 ]
Harnett, J. [3 ]
Glue, P. [4 ]
机构：
[1] Pfizer Inc, Statistics, New York, NY USA
[2] Nathan S Kline Inst Psychiat Res, New York, NY USA
[3] Pfizer Inc, Global Outcomes, New York, NY USA
[4] Pfizer Inc, Clin Sci Grp, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [21] The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
    Na, Kyoungsae
    Jung, Han-Yong
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 193 - 193
  • [22] Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder
    DelBello, Melissa P.
    Versavel, Mark
    Ice, Kathleen
    Keller, David
    Miceli, Jeffrey
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2008, 18 (05) : 491 - 499
  • [23] The Effectiveness of Cross-Tapering Switching to Ziprasidone in Patients with Schizophrenia or Schizoaffective Disorder
    Ko, Young-Hoon
    Na, Kyoung-Sae
    Kim, Chul-Eung
    Kim, Seung-Hyun
    Jeon, Yang-Whan
    Yi, Jung-Sec
    Lee, Moon-Soo
    Kim, Shin-Gyeom
    Jeong, Hyun-Ghang
    Jung, Han-Yong
    PSYCHIATRY INVESTIGATION, 2014, 11 (04) : 459 - 466
  • [24] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    Hill, AL
    Tollefson, GD
    BIOLOGICAL PSYCHIATRY, 2004, 55 : 185S - 186S
  • [25] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, BJ
    Lipkovich, I
    Edwards, SE
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 491 - 491
  • [26] Effectiveness and Tolerability of Oral Ziprasidone in Psychiatric Inpatients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder: A Multicenter, Prospective, and Naturalistic Study
    Diaz-Marsa, Marina
    Sanchez, Sara
    Rico-Villademoros, Fernando
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (04) : 509 - 517
  • [27] Improvement of comorbid depression with olanzapine versus ziprasidone treatment in patients with schizophrenia or schizoaffective disorder
    Kinon, B
    Lipkovich, I
    Edwards, S
    Hill, A
    Ahl, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 163 - 163
  • [28] Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder
    Miceli, Jeffrey J.
    Tensfeldt, Thomas G.
    Shiovitz, Thomas
    Anziano, Richard
    O'Gorman, Cedric
    Harrigan, Rachel H.
    PHARMACOTHERAPY, 2010, 30 (02): : 127 - 135
  • [29] CHQ and CGAS in an open-label study of ziprasidone in pediatric patients with bipolar disorder, schizophrenia, or schizoaffective disorder
    DelBello, Melissa
    Stewart, Michelle
    Versavel, Mark
    Keller, David
    Miceli, Jeffrey
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (06) : 662 - 662
  • [30] Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo controlled trial
    Keck, P
    Buffenstein, A
    Ferguson, J
    Feighner, J
    Jaffe, W
    Harrigan, EP
    Morrissey, MR
    PSYCHOPHARMACOLOGY, 1998, 140 (02) : 173 - 184
12345